cytarabine has been researched along with deferoxamine in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (38.46) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Barbieri, R; Feriotto, G; Gambari, R; Nastruzzi, C | 1 |
| Cohen, A; Estrov, Z; Freedman, MH; Gelfand, EW | 1 |
| Barbieri, R; Feriotto, G; Gambari, R; Nastruzzi, C; Traniello, F | 1 |
| Cohen, A; Dubé, ID; Estrov, Z; Freedman, MH; Gelfand, EW; Sulh, H; Tawa, A; Wang, XH | 1 |
| Brockman, RW | 1 |
| Fukuchi, K; Gomi, K; Tomoyasu, S; Tsuruoka, N; Watanabe, H | 1 |
| Abbruzzese, A; Bianco, AR; Caraglia, M; De Lorenzo, S; Fabbrocini, A; Leardi, A; Musicò, M; Notaro, R; Pepe, S; Pizzi, C; Selleri, C; Tagliaferri, P | 1 |
| Fukuchi, K; Gomi, K; Nakamaki, T; Tomoyasu, S; Tsuruoka, N | 1 |
| Abbruzzese, A; Budillon, A; Caraglia, M; Tagliaferri, P | 1 |
| Knodler, LA; Saldaña-Ahuactzi, Z | 1 |
2 review(s) available for cytarabine and deferoxamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Biochemical aspects of drug combinations.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Bleomycin; Camptothecin; Cell Division; Cytarabine; Deferoxamine; Diamines; DNA, Neoplasm; Doxorubicin; Drug Therapy, Combination; Leukemia L1210; Macromolecular Substances; Mice; Neoplasms; Neoplasms, Experimental; Nitrosourea Compounds; Purine Nucleotides; Ribonucleotide Reductases; Thioguanine; Triazoles | 1974 |
11 other study(ies) available for cytarabine and deferoxamine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Induction to erythroid differentiation of K562 cells by 1-beta-D-arabinofuranosylcytosine is inhibited by iron chelators: reversion by treatment with hemin.
Topics: Cell Differentiation; Cell Line; Cytarabine; Deferoxamine; Erythropoiesis; Growth Inhibitors; Heme; Hemin; Hemoglobins; Humans; Kinetics; Leukemia, Erythroblastic, Acute | 1988 |
Synergistic antiproliferative effects on HL-60 cells: deferoxamine enhances cytosine arabinoside, methotrexate, and daunorubicin cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Cell Line; Cytarabine; Daunorubicin; Deferoxamine; Dose-Response Relationship, Drug; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Methotrexate; Tumor Cells, Cultured | 1988 |
Hemin uptake by erythroleukemic cells treated with iron chelators: effects on the induced expression of differentiated functions.
Topics: Cell Line; Cytarabine; Deferoxamine; Heme; Hemin; Hemoglobins; Humans; Leukemia, Erythroblastic, Acute | 1987 |
In vitro and in vivo effects of deferoxamine in neonatal acute leukemia.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; B-Lymphocytes; Cell Differentiation; Cell Division; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; Cytarabine; Daunorubicin; Deferoxamine; Drug Resistance; Female; Humans; Indoles; Infant, Newborn; Leukemia, Lymphoid; Prednisone; Translocation, Genetic; Vincristine | 1987 |
G1 accumulation caused by iron deprivation with deferoxamine does not accompany change of pRB status in ML-1 cells.
Topics: Cell Division; Cell Line; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Cytarabine; Deferoxamine; Etoposide; Gene Expression; Humans; Phosphorylation; Proto-Oncogene Proteins; Retinoblastoma Protein; RNA, Messenger; Tumor Suppressor Protein p53 | 1997 |
Desferioxamine increases iron depletion and apoptosis induced by ara-C of human myeloid leukaemic cells.
Topics: Acute Disease; Antidotes; Antimetabolites, Antineoplastic; Apoptosis; Cell Division; Cytarabine; Deferoxamine; Drug Interactions; Drug Synergism; HL-60 Cells; Humans; Iron; Leukemia, Myeloid; Receptors, Transferrin; Tumor Cells, Cultured | 1998 |
DNA damage induces p21 protein expression by inhibiting ubiquitination in ML-1 cells.
Topics: Acetylcysteine; Cell Nucleus; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Proteinase Inhibitors; Cytarabine; Deferoxamine; DNA Damage; Etoposide; Gene Expression Regulation; Hydroxyurea; Polyribosomes; RNA, Messenger; Tumor Cells, Cultured; Ubiquitins | 1998 |
Post-translational modifications of eukaryotic initiation factor-5A (eIF-5A) as a new target for anti-cancer therapy.
Topics: Antineoplastic Agents; Cell Cycle; Cell Death; Chelating Agents; Cytarabine; Deferoxamine; Epidermal Growth Factor; ErbB Receptors; Eukaryotic Translation Initiation Factor 5A; Exotoxins; Humans; Interferon-gamma; Iron; Kinetics; Leukemia; Lysine; Oropharyngeal Neoplasms; Peptide Initiation Factors; Protein Processing, Post-Translational; RNA-Binding Proteins; Transforming Growth Factor alpha; Tumor Cells, Cultured | 1999 |
FoxR is an AraC-like transcriptional regulator of ferrioxamine uptake in Salmonella enterica.
Topics: Bacterial Outer Membrane Proteins; Bacterial Proteins; Cytarabine; Deferoxamine; Ferrichrome; Gene Expression Regulation, Bacterial; Iron; Salmonella enterica; Siderophores; Transcription Factors | 2022 |